Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
:) It would be beautiful if it worked that way, it does not. Had many shares at that price, they just kept up with the rev. splits until all shares were gone. Then I of course had to pay e-trade , I think it was 27.00 for the sweep they did on my account. So no million dollars.
If you look at there history . It is only triple because they keep doing reverse splits , and they keep reverse splitting until you have no shares left. And then the start all over again
WOW . I would love to hear the response to that one!
By the way that is about the only promise they have ever kept
of course IMO
Yea,,, and after there reverse split stocks were worth 11.00 per share .. that lasted about 5 min
http://www.prnewswire.com/news-releases/geovax-labs-announces-reverse-stock-split-applies-for-listing-on-nasdaq-91058834.html
I did see that on my google finance page ... last week
nothing new,,, but not a downward trend ... loss is .01 per share... compared to .06
http://yankeeanalysts.com/2016/11/10/trading-radar-zooming-in-on-shares-of-geovax-labs-inc-govx/
We can also take a look at the Average Directional Index or ADX of the stock. For traders looking to capitalize on trends, the ADX may be an essential technical tool. The ADX is used to measure trend strength. ADX calculations are made based on the moving average price range expansion over a specified amount of time. ADX is charted as a line with values ranging from 0 to 100. The indicator is non-directional meaning that it gauges trend strength whether the stock price is trending higher or lower. The 14-day ADX for GeoVax Labs Inc. (GOVX) presently sits at 41.84. In general, and ADX value from 0-25 would represent an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would indicate a very strong trend, and a value of 75-100 would signify an extremely strong trend.
GeoVax Reports Progress With Hemorrhagic Fever Vaccine Program
Vaccine to Address Four Major Hemorrhagic Fever Viruses -- Ebola, Sudan, Marburg, and Lassa; VLP Production Now Demonstrated for All Virus Targets
ATLANTA, GA - (NewMediaWire) - July 27, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today provided an update on its Tetravalent Hemorrhagic Fever Vaccine (THV) program, including a demonstration that its vaccines produce non-infectious virus-like particles (VLPs) for each of the four virus targets -- Ebola-Zaire, Ebola-Sudan, Marburg, and Lassa.
GeoVax's vaccine (GOVX- E303) is based on the Company's novel Modified Vaccinia Ankara (MVA) VLP platform, which generates noninfectious VLPs. VLPs, expressed by MVA, form the base for a highly effective vaccine, because they can be engineered to display native forms of membrane-anchored viral envelope glycoproteins that mimic a natural infection. These native proteins trigger the body to produce antibody responses that are highly effective in their ability to block virus infections. Moreover, VLPs generated by GeoVax's vaccines are produced in vivo (in the very person being vaccinated) and do not have to be purified, thereby reducing manufacturing costs.
GeoVax has previously demonstrated VLP formation as well as 100% protection in non-human primates after single, or prime/boost, inoculations with its Ebola-Zaire vaccine. The Zaire strain of Ebola virus was responsible for the 2014/15 outbreak in West Africa, which resulted in 28,652 infections and 11,325 deaths. The Company now has vaccine constructs against each of the three additional hemorrhagic fever targets and has demonstrated VLP production for each target infection. GeoVax's vaccines are being developed for use as either individual vaccines in epidemic or biothreat situations or combined as a single tetravalent vaccine for protection of the millions of individuals who live in at-risk areas, travelers, military personnel, and healthcare workers.
Thin section electron micrographs of MVA-VLP vaccines for Zaire (EBOV), Sudan (SUDV), Marburg (MARV) and Lassa (LASV). Non-infectious VLPs budding from the surface of the cells resemble native virions. Immunogold staining was performed using antibodies specific to the glycoproteins of Zaire, Sudan and Marburg viruses (see arrows for examples of gold particles). Lassa VLPs (not immunogold stained) are 100-200 nm in diameter and contain granular structures similar in size to cellular ribosomes, 10 ~ 20 nm (large arrow points to the largest VLP in a cluster of four).
Farshad Guirakhoo, Ph.D., GeoVax's Senior Vice President of Research and Development, commented, "Hemorrhagic fevers caused by filoviruses (Ebola, Sudan, and Marburg viruses) and arenaviruses, such as Lassa virus, occur in an overlapping geographical region in West Africa, putting as many as 200 million people at risk of infection with no licensed vaccines or effective therapeutics available. Lassa virus is endemic and causes severe and often fatal hemorrhagic illness with as many as 67,000 deaths per year. Although many consider MVA a boosting, not a priming, vaccine, our MVA-expressed VLPs are in fact outstanding priming vaccines. In non-human primates, we have demonstrated that a single dose of the GeoVax Ebola-Zaire vaccine elicits complete protective immunity; an important attribute for a vaccine which can be used for travelers or to stem an ongoing epidemic/endemic situation."
Robert McNally, Ph.D., GeoVax's President and CEO, said, "The lessons learned from the 2014/15 Ebola outbreak indicate that the urbanization of Africa contributes to the rapid spread of emergent viruses. If not contained, they can cause global epidemics. The commercial opportunity for our HFV vaccine program is very attractive, particularly for Lassa fever, given the endemic nature of the virus. Currently, ribavirin is used for Lassa fever treatment, but it seems to be effective only if given early on in the course of clinical illness. These viruses could also be intentionally used as biological warfare agents, which makes vaccine development against these agents of high interest to the U.S. Department of Defense and related agencies."
About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika Virus, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa). GeoVax also recently began programs to evaluate the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
CONTACT INFORMATION
•
GeoVax Labs, Inc.
Robert T. McNally, Ph.D.
investor@geovax.com
678-384-7220
GeoVax Ebola Vaccine Protects Non-Human Primates Against Lethal Challenge
Single Dose Provided 100% Protection, Tetravalent Hemorrhagic Fever Virus Vaccine Under Development
ATLANTA, GA - (NewMediaWire) - June 01, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that testing of its Ebola vaccine in non-human primates showed 100% protection against a lethal Ebola virus challenge.
The GeoVax Ebola vaccine is based on the Company's novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated. VLPs mimic a natural infection, triggering the body to produce a robust and durable immune response with both antibodies and T cells. The GeoVax MVA-VLP platform has already demonstrated outstanding safety in four clinical trials for the Company's HIV vaccine candidates, which included 500 participants.
In this study, GeoVax's MVA-VLP vaccine against Ebola virus (Zaire ebolavirus; the cause of the 2014 outbreak) was administered as either a single inoculation (prime) or as two inoculations at a four week interval (prime-boost) to groups of four rhesus macaques each. A control group received the MVA vector without Ebola virus protein inserts. Four weeks after inoculation, animals in all three groups were exposed to a lethal dose of Ebola virus. Three of the four unvaccinated animals died within 12 days, while all of the vaccinated animals survived. Researchers at Rocky Mountain Laboratories, part of the National Institute of Allergy and Infectious Diseases (NIAID), collaborated in the study.
"This trial is particularly encouraging because it shows that a single dose of our MVA-VLP Ebola vaccine is sufficient for protection against a lethal challenge. This is not only important for the control of natural Ebola outbreaks, but also for rapid control of Ebola intentionally released as a bioterrorism agent," said Dr. Farshad Guirakhoo, Ph.D., GeoVax's Senior Vice President, Research and Development.
GeoVax's MVA-VLP vaccine against the Ebola virus is one component of a tetravalent hemorrhagic fever virus vaccine being developed by GeoVax. The other components are Sudan virus (Sudan ebolavirus), Marburg virus, and Lassa virus MVA-VLP vaccines. These vaccines are envisioned as either individual vaccines in epidemic situations or combined as a tetravalent vaccine for the protection of the millions of individuals who live in at-risk areas, travelers, military personnel, healthcare workers, and others.
Robert McNally, PhD., GeoVax's President & CEO, commented, "We are very pleased with the results of this study, and now turn our attention to completing characterization and testing of our tetravalent vaccine. This proof-of-concept study in non-human primates for the Zaire ebolavirus component of our tetravalent vaccine gives us very high confidence in our program."
About Hemorrhagic Fever Viruses
Hemorrhagic fevers caused by Filoviruses (Ebola virus, Sudan virus, and Marburg virus) and Arenaviruses, such as Lassa virus, are considered neglected infectious diseases with no licensed vaccines or effective therapeutics available. Currently, for Lassa fever treatment, ribavirin is used but it is only effective if given within the first 6 days after disease onset. These viral hemorrhagic fevers are epidemic/endemic in 22 African countries, and could be intentionally used as biological warfare agents. The 2014 Ebola outbreak in western Africa was the 28th recorded outbreak of the Ebola virus, infecting 28,652 individuals resulting in 11,325 deaths. Lassa virus causes severe and often fatal hemorrhagic illness in an overlapping geographical region with Filoviruses. In contrast to the unpredictable epidemics of filoviruses, Lassa virus is endemic in West Africa with an annual incidence of >300,000 infections, resulting in 5,000-10,000 deaths. Data from a recent sero-epidemiologic study suggest that the number of annual Lassa virus cases may be much higher, reaching three million infections and 67,000 deaths, putting as many as 200 million persons at risk (Leski TA, et al., Emerging Infectious Diseases 21 (2015)). The lessons learned from the recent Ebola outbreak indicate that the urbanization of Africa contributes to the rapid spread of such pathogens. If not contained, they can cause global epidemics.
About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company's most advanced development programs are focused on vaccines against HIV and hemorrhagic fever viruses (Ebola virus, Sudan virus, Marburg virus, and Lassa virus). In addition, GeoVax recently initiated vaccine development against Zika virus, and evaluation of its MVA-VLP platform in cancer immunotherapy. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.
Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with NIAID funding. Overall, GeoVax's HIV vaccines, in various doses and combinations, have been tested in 500 humans with very encouraging results. Currently, GeoVax has the most advanced vaccine for the subtype of HIV prevalent in North America and Western Europe. The company awaits funding for a Phase 2b efficacy trial to prove the vaccine protects against HIV. For more information, visit www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
CONTACT INFORMATION
GeoVax Labs, Inc.
Robert T. McNally, Ph.D.
678-384-7220
investor@geovax.com
GeoVax Presents at Zika Virus Scientific Conference
http://www.digitaljournal.com/pr/2923117
Geovax MVA-VLP vaccine vector has been proven safe in multiple human clinical trials Source text for Eikon: Further company coverage: [GOVX.PK ] )
http://www.ubs.wallst.com/ubs/mkt_story.asp?docKey=1329-ASC08LH6-1&first=0
GeoVax Now Collaborating With CDC and University of Georgia
ATLANTA, GA - (NewMediaWire) - March 30, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has entered into a Research Collaboration Agreement with the Centers for Disease Control and Prevention (CDC) to evaluate the immunogenicity and protective efficacy of its Zika virus vaccine.
JPO Solutions Inc. (MOP Environmental) Launches New RigBlend Product
News Release
For Immediate Release
March 17, 2016
http://www.jpoabsorbents.com/2016/03/18/jpo-solutions-inc-mop-environmental-launches-new-rigblend-product/
Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates
Simian Analogue of HIV Vaccine Being Evaluated in Human Clinical Trials
ATLANTA, GA - (NewMediaWire) - March 07, 2016 - GeoVax Labs. Inc. (OTCQB: GOVX) today announced that the simian analogue of the company's human immunodeficiency virus (HIV) vaccine, GOVX-B11, provided a 76 percent reduction in per exposure risk of simian immunodeficiency virus (SIV) infection in young adult rhesus macaques. Per exposure risk was assessed over 12 weekly rectal exposures. The study, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), also showed the vaccine providing much better protection for young adult than middle-aged and older macaques.
The test vaccine used a DNA vaccine expressing non-infectious virus-like particles (VLPs) to prime the immune response and a modified vaccinia Ankara (MVA) vaccine, also expressing non-infectious VLPs, to boost the primed response. The vaccine regimen included two DNA primes at weeks 0 and 8 followed by two MVA boosts at weeks 16 and 32. The efficacy of the vaccine was tested at 6 months after the final MVA boost by 12 weekly rectal exposures to a pathogenic SIV given at a dose that infected approximately 30 percent of the unvaccinated animals at each challenge. Animals that were less than 10 years old (estimated human age of about 40) had much better protection than those over 10 years old. The age-dependence for protection was stronger than typically seen for vaccines and likely reflects the HIV target for protective antibody being particularly well-camouflaged.
The human version of the vaccine, GOVX-B11, has undergone clinical testing through the NIAID-supported HIV Vaccine Trials Network (HVTN) in Phase 1 and 2a trials involving about 500 individuals. These trials have shown the vaccine to have excellent safety and reproducible ability to elicit immune responses. Based on the results of the clinical trials, as well as the current preclinical trial, further evaluation of the GOVX-B11 vaccine in humans will use two DNA primes followed by three MVA boosts with the 16 week rest used in this trial between the last two MVA boosts.
"This trial showed strong protection in young adults for the simian version of our GOVX-B11 HIV vaccine," said GeoVax Chief Scientific Officer, Harriet L. Robinson, Ph.D. "We did not anticipate the extent of the age-dependence of protection, which suggests that people younger than 40 will respond better to HIV vaccines than older individuals. The most rapid increase in infections in the United States is in 13 to 24 year olds, an age range that should respond very well to the vaccine. In this age group, infections increased at a rate of 10.5% per year between 2002 and 2011. This study furthers our resolve to advance GOVX-B11 in human clinical trials."
The study was a collaborative effort between the NIAID's Simian Vaccine Evaluation Unit (SVEU) which conducted the study, and the Yerkes National Primate Research Center where assays for antibody and T cell responses were conducted.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Virus Ankara-Virus Like Particle (MVA-VLP) vaccine platform. The Company's most advanced development programs are focused on vaccines against HIV and hemorrhagic fever viruses (Ebola, Marburg and Lassa). Recently these efforts have been extended to Zika virus. GeoVax's vaccine platform supports production of non-infectious VLPs in the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear. GeoVax also recently began a program to evaluate the use of its MVA-VLP platform in cancer immunotherapy.
About Yerkes National Primate Research Center
For eight decades, the Yerkes National Primate Research Center, Emory University, has been dedicated to conducting essential basic science and translational research to advance scientific understanding and to improve the health and well-being of humans and nonhuman primates. Today, the center, as one of only eight National Institutes of Health-funded national primate research centers, provides leadership, training and resources to foster scientific creativity, collaboration and discoveries. Yerkes-based research is grounded in scientific integrity, expert knowledge, respect for colleagues, an open exchange of ideas and compassionate quality animal care.
Within the fields of microbiology and immunology, neurologic diseases, neuropharmacology, behavioral, cognitive and developmental neuroscience, and psychiatric disorders, the center's research programs are seeking ways to: develop vaccines for infectious and noninfectious diseases; understand the basic neurobiology and genetics of social behavior and develop new treatment strategies for improving social functioning in ASD and schizophrenia; interpret brain activity through imaging; increase understanding of progressive illnesses such as Alzheimer's and Parkinson's diseases; unlock the secrets of memory; treat drug addiction; determine how the interaction between genetics and society shape who we are; and advance knowledge about the evolutionary links between biology and behavior.
Journal Reference:
1. Strong, but Age-Dependent, Protection Elicited by a DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Venkateswarlu Chamcha, Sunil Kannanganat, Sailaja Gangadhara, Rafik Nabi, Pamela A. Kozlowski, David C. Montefiori, Celia C. LaBranche, Jens Wrammert, Brandon F. Keele, Harikrishnan Balachandran, Sujata Sahu, Michelle Lifton, Sampa Santra, Rahul Basu, Bernard Moss, Harriet L. Robinson, Rama Rao Amara. Open Forum Infect Dis (2016) doi: 10.1093/ofid/ofw034 First published online: February 11, 2016
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
CONTACT INFORMATION
Robert T. McNally, Ph.D.
GeoVax Labs, Inc.
investor@geovax.com
678-384-7220
Why would anyone buy this stock after hours?
0.00500
-0.00145 (-22.48%)
After Hours: 0.00455 0.00000 (0.00%)
Feb 12, 4:03PM EST
Currency in USD
Range 0.00 - 0.00
52 week 0.00 - 0.02
Open 0.00
Vol / Avg. 423,600.00/157,248.00
Mkt cap 15.73M
P/E -
Div/yield -
EPS -
Shares 2.00B
Beta 1.04
Inst. own 0%
excellent.. then lets hope this time ,it is real
that's only because you were not here for the reverse split that took this stock to 11 dollars ... and left us with no shares and then went to the basement.
Same PR every time, just a different virus .. something happens in the world, they have the cure... Problem is, nothing ever goes to market.IMO
I agree
JPO Solutions Inc. (Formerly MOP Environmental) Inks Distribution Agreement with HYNAC Oil & Gas of China
http://www.baystreet.ca/viewarticle.aspx?id=432570
JPO Solutions Inc. Hosts 2 Day Meeting with Distributors and Investors
http://www.jpoabsorbents.com/news/